(Boursier.com) — Boiron stands out this weekend, up 3.3% to 40.80 euros, while the broker Oddo BHF revalued the laboratory from 57 to 60 euros with an opinion to ‘outperform’… Driven by a very strong rebound in its activity in the first quarter, the company achieved a turnover of 145.78 million euros, up 59.9% (+58% at constant exchange rates). Historic growth for the group. The company benefited from the base effect from the sharp drop that had marked the first quarter of 2021 in the context of the health crisis, the growth in homeopathic specialties, the rise in other health products and the continued the innovation strategy.
Management now anticipates growth in turnover in 2022, even if sales will be “potentially impacted by the current geopolitical context”…
New product launches (gradual diversification, bolt-on acquisition options), cost reduction and favorable base effects (after 3 years of decline in HNC France sales, due to delisting) are all assets for this file, not to mention a very solid financial situation with net cash of 234 ME at the end of 2021.
©2022 Boursier.com